Krzysztof Ozierański1, Paweł Balsam2, Agnieszka Kapłon-Cieślicka1, Agata Tymińska1, Robert Kowalik1, Marcin Grabowski1, Michał Peller1, Anna Wancerz1, Michał Marchel1, Maria G Crespo-Leiro3, Aldo P Maggioni4,5, Jarosław Drożdż6, Krzysztof J Filipiak1, Grzegorz Opolski1. 1. Department of Cardiology, Public Central Teaching Hospital in Warsaw, Medical University of Warsaw, 1a Banacha St., 02-097, Warsaw, Poland. 2. Department of Cardiology, Public Central Teaching Hospital in Warsaw, Medical University of Warsaw, 1a Banacha St., 02-097, Warsaw, Poland. pawel.balsam@wum.edu.pl. 3. Unidad de Insuficiencia Cardiaca Avanzada y Trasplante Cardiaco, Hospital Universitario A Coruna, CIBERCV, La Coruna, Spain. 4. ANMCO Research Centre, Florence, Italy. 5. EURObservational Research Programme, European Society of Cardiology, Sophia Antipolis, France. 6. Department of Cardiology, Cardiology and Cardiac Surgery, Medical University of Lodz, Lodz, Poland.
Abstract
PURPOSE: Current clinical recommendations do not emphasise superiority of any of diuretics, but available reports are very encouraging and suggest beneficial effects of torasemide. This study aimed to compare the effect of torasemide and furosemide on long-term outcomes and New York Heart Association (NYHA) class change in patients with chronic heart failure (HF). METHODS: Of 2019 patients enrolled in Polish parts of the heart failure registries of the European Society of Cardiology (Pilot and Long-Term), 1440 patients treated with a loop diuretic were included in the analysis. The main analysis was performed on matched cohorts of HF patients treated with furosemide and torasemide using propensity score matching. RESULTS: Torasemide was associated with a similar primary endpoint (all-cause death; 9.8% vs. 14.1%; p = 0.13) occurrence and 23.8% risk reduction of the secondary endpoint (a composite of all-cause death or hospitalisation for worsening HF; 26.4% vs. 34.7%; p = 0.04). Treatment with both torasemide and furosemide was associated with the significantly most frequent occurrence of the primary (23.8%) and secondary (59.2%) endpoints. In the matched cohort after 12 months, NYHA class was higher in the furosemide group (p = 0.04), while furosemide use was associated with a higher risk (20.0% vs. 12.9%; p = 0.03) of worsening ≥ 1 NYHA class. Torasemide use impacted positively upon the primary endpoint occurrence, especially in younger patients (aged < 65 years) and with dilated cardiomyopathy. CONCLUSIONS: Our findings contribute to the body of research on the optimal diuretic choice. Torasemide may have advantageous influence on NYHA class and long-term outcomes of HF patients, especially younger patients or those with dilated cardiomyopathy, but it needs further investigations in prospective randomised trials.
PURPOSE: Current clinical recommendations do not emphasise superiority of any of diuretics, but available reports are very encouraging and suggest beneficial effects of torasemide. This study aimed to compare the effect of torasemide and furosemide on long-term outcomes and New York Heart Association (NYHA) class change in patients with chronic heart failure (HF). METHODS: Of 2019 patients enrolled in Polish parts of the heart failure registries of the European Society of Cardiology (Pilot and Long-Term), 1440 patients treated with a loop diuretic were included in the analysis. The main analysis was performed on matched cohorts of HF patients treated with furosemide and torasemide using propensity score matching. RESULTS:Torasemide was associated with a similar primary endpoint (all-cause death; 9.8% vs. 14.1%; p = 0.13) occurrence and 23.8% risk reduction of the secondary endpoint (a composite of all-cause death or hospitalisation for worsening HF; 26.4% vs. 34.7%; p = 0.04). Treatment with both torasemide and furosemide was associated with the significantly most frequent occurrence of the primary (23.8%) and secondary (59.2%) endpoints. In the matched cohort after 12 months, NYHA class was higher in the furosemide group (p = 0.04), while furosemide use was associated with a higher risk (20.0% vs. 12.9%; p = 0.03) of worsening ≥ 1 NYHA class. Torasemide use impacted positively upon the primary endpoint occurrence, especially in younger patients (aged < 65 years) and with dilated cardiomyopathy. CONCLUSIONS: Our findings contribute to the body of research on the optimal diuretic choice. Torasemide may have advantageous influence on NYHA class and long-term outcomes of HF patients, especially younger patients or those with dilated cardiomyopathy, but it needs further investigations in prospective randomised trials.
Authors: Paweł Balsam; Krzysztof Ozierański; Michał Marchel; Monika Gawałko; Łukasz Niedziela; Agata Tymińska; Bartosz Sieradzki; Maciej Sieradzki; Anna Fojt; Elwira Bakuła; Renata Główczyńska; Michał Peller; Maciej Markulis; Janusz Bednarski; Robert Kowalik; Andrzej Cacko; Grzegorz Niewiński; Krzysztof J Filipiak; Grzegorz Opolski; Marcin Grabowski Journal: Cardiol J Date: 2020-01-07 Impact factor: 2.737
Authors: Beatrice Besche; Thomas Blondel; Emilie Guillot; Catherine Garelli-Paar; Mark A Oyama Journal: J Vet Intern Med Date: 2020-08-07 Impact factor: 3.333
Authors: Salva R Yurista; Herman H W Silljé; Harry van Goor; Jan-Luuk Hillebrands; Hiddo J L Heerspink; Luiz de Menezes Montenegro; Silke U Oberdorf-Maass; Rudolf A de Boer; B Daan Westenbrink Journal: Cardiovasc Drugs Ther Date: 2020-06 Impact factor: 3.947